Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

Fineline Cube Jun 5, 2024

MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company Deals

Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases

Fineline Cube Jun 5, 2024

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP

Fineline Cube Jun 4, 2024

Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...

Company Medical Device

Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China

Fineline Cube Jun 4, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Deals Drug

Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody

Fineline Cube Jun 4, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...

Company Drug

Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs

Fineline Cube Jun 4, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...

Company

China Meheco Group Appoints Yang Guang as Chairman and Legal Representative

Fineline Cube Jun 4, 2024

China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...

Company Drug

Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China

Fineline Cube Jun 4, 2024

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...

Company Drug

Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT

Fineline Cube Jun 4, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...

Company Medical Device

Varian Medical Gets China Approval for Fourth-Generation Halcyon Radiotherapy System

Fineline Cube Jun 4, 2024

Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza

Fineline Cube Jun 4, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns

Fineline Cube Jun 4, 2024

FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...

Company Drug

Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers

Fineline Cube Jun 4, 2024

Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...

Company Deals

Changchun GeneScience to Distribute TWi Pharma’s Megestrol in China and Southeast Asia

Fineline Cube Jun 4, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a biopharmaceutical company based in China, has entered into an...

Policy / Regulatory

China’s NHSA and MoF Plan Expansion of Long-term Care Insurance System Pilot Program

Fineline Cube Jun 4, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...

Company Drug

Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors

Fineline Cube Jun 4, 2024

Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...

Policy / Regulatory

Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released

Fineline Cube Jun 4, 2024

The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug...

Company Drug

Bristol Myers Squibb’s Krazati Meets Primary Endpoint in Late-Stage Lung Cancer Study

Fineline Cube Jun 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage study for its KRAS...

Company Medical Device

Hygea Medical’s Subsidiary Gets Green Light for Innovative Intrahepatic Puncture Instrument in China

Fineline Cube Jun 3, 2024

Hygea Medical Technology Co., Ltd, a China-based medical device company, has announced that its subsidiary,...

Posts pagination

1 … 296 297 298 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.